I agree with you. None of the news has helped the stock so far including JAMA, TLD, MIA, etc. My sense is MHRA approval is unlikely to give us the valuation we deserve either unless there is some additional surprise coupled with it such as FDA or EU application submission guidance and/or couple hundred million in non dilutive funding from big pharma. A PR around one of this initiative will force the market makers to give us at least $4-5B market cap valuation in no time.
Market Data 
Markets 
AI
